# Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome

> **NCT05926505** · PHASE2,PHASE3 · RECRUITING · sponsor: **Hellenic Institute for the Study of Sepsis** · enrollment: 182 (estimated)

## Conditions studied

- Post-Acute COVID-19 Syndrome
- Post-Acute COVID-19
- Long COVID

## Interventions

- **DRUG:** Placebo
- **DRUG:** Anakinra 149 MG/ML Prefilled Syringe [Kineret]

## Key facts

- **NCT ID:** NCT05926505
- **Lead sponsor:** Hellenic Institute for the Study of Sepsis
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-06
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2026-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05926505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05926505, "Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05926505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*